When to treat myelodysplastic syndromes

Mojtaba Akhtari

Research output: Contribution to journalArticle

4 Citations (Scopus)

Abstract

The myelodysplastic syndromes represent a heterogeneous series of clonal hematologic neoplasms characterized by morphologic dysplasia, aberrant hematopoiesis and a variable risk of progression to acute myeloid leukemia. These syndromes have a complex pathobiology, and ineffective hematopoiesis is a well-recognized feature of all of them. Normal blood cell maturation, differentiation, function, and survival are impaired, and these abnormalities contribute to the development of peripheral blood pancytopenia. The majority of patients succumb to complications of either bone marrow failure or leukemic progression. The fact that the majority of patients are elderly and have other comorbidities complicates therapeutic decision making and necessitates the development of individualized treatment strategies.

Original languageEnglish (US)
JournalONCOLOGY
Volume25
Issue number6
StatePublished - Jan 1 2011

Fingerprint

Myelodysplastic Syndromes
Hematopoiesis
Pancytopenia
Hematologic Neoplasms
Acute Myeloid Leukemia
Comorbidity
Cell Differentiation
Blood Cells
Decision Making
Bone Marrow
Survival
Therapeutics

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

When to treat myelodysplastic syndromes. / Akhtari, Mojtaba.

In: ONCOLOGY, Vol. 25, No. 6, 01.01.2011.

Research output: Contribution to journalArticle

Akhtari, M 2011, 'When to treat myelodysplastic syndromes', ONCOLOGY, vol. 25, no. 6.
Akhtari M. When to treat myelodysplastic syndromes. ONCOLOGY. 2011 Jan 1;25(6).
Akhtari, Mojtaba. / When to treat myelodysplastic syndromes. In: ONCOLOGY. 2011 ; Vol. 25, No. 6.
@article{281b24d02c35438196d70a9af83c4a38,
title = "When to treat myelodysplastic syndromes",
abstract = "The myelodysplastic syndromes represent a heterogeneous series of clonal hematologic neoplasms characterized by morphologic dysplasia, aberrant hematopoiesis and a variable risk of progression to acute myeloid leukemia. These syndromes have a complex pathobiology, and ineffective hematopoiesis is a well-recognized feature of all of them. Normal blood cell maturation, differentiation, function, and survival are impaired, and these abnormalities contribute to the development of peripheral blood pancytopenia. The majority of patients succumb to complications of either bone marrow failure or leukemic progression. The fact that the majority of patients are elderly and have other comorbidities complicates therapeutic decision making and necessitates the development of individualized treatment strategies.",
author = "Mojtaba Akhtari",
year = "2011",
month = "1",
day = "1",
language = "English (US)",
volume = "25",
journal = "Oncology",
issn = "0890-9091",
publisher = "UBM Medica Healthcare Publications",
number = "6",

}

TY - JOUR

T1 - When to treat myelodysplastic syndromes

AU - Akhtari, Mojtaba

PY - 2011/1/1

Y1 - 2011/1/1

N2 - The myelodysplastic syndromes represent a heterogeneous series of clonal hematologic neoplasms characterized by morphologic dysplasia, aberrant hematopoiesis and a variable risk of progression to acute myeloid leukemia. These syndromes have a complex pathobiology, and ineffective hematopoiesis is a well-recognized feature of all of them. Normal blood cell maturation, differentiation, function, and survival are impaired, and these abnormalities contribute to the development of peripheral blood pancytopenia. The majority of patients succumb to complications of either bone marrow failure or leukemic progression. The fact that the majority of patients are elderly and have other comorbidities complicates therapeutic decision making and necessitates the development of individualized treatment strategies.

AB - The myelodysplastic syndromes represent a heterogeneous series of clonal hematologic neoplasms characterized by morphologic dysplasia, aberrant hematopoiesis and a variable risk of progression to acute myeloid leukemia. These syndromes have a complex pathobiology, and ineffective hematopoiesis is a well-recognized feature of all of them. Normal blood cell maturation, differentiation, function, and survival are impaired, and these abnormalities contribute to the development of peripheral blood pancytopenia. The majority of patients succumb to complications of either bone marrow failure or leukemic progression. The fact that the majority of patients are elderly and have other comorbidities complicates therapeutic decision making and necessitates the development of individualized treatment strategies.

UR - http://www.scopus.com/inward/record.url?scp=79956352622&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=79956352622&partnerID=8YFLogxK

M3 - Article

VL - 25

JO - Oncology

JF - Oncology

SN - 0890-9091

IS - 6

ER -